DeMario M D, Liebowitz D N
Department of Medicine, University of Chicago, IL 60637, USA.
Semin Oncol. 1998 Aug;25(4):492-502.
Lymphoma is a common opportunistic complication of immunosuppression. Lymphomas in patients with the acquired immunodeficiency syndrome (AIDS) may broadly be divided into four major types: intermediate- or high-grade systemic lymphoma, primary central nervous system (CNS) lymphoma, Hodgkin's disease (HD) and primary effusion lymphoma. Multiple active regimens have been identified for patients with AIDS-related systemic lymphoma. However, despite high initial complete response rates, most studies have reported a median survival of less than 1 year for these patients, with approximately half of the patients dying from lymphoma and half from opportunistic infections or other AIDS-related complications. The standard therapeutic approach for patients with AIDS-related primary CNS lymphoma is radiotherapy, although recent studies using combinations of chemotherapy with radiotherapy may offer an improvement in therapy for this group of patients who have very poor overall prognosis. Lymphoproliferative disease in patients after solid organ or bone marrow transplantation represents with a spectrum of disorders. No standard approach for therapy in this group of patients has been clearly established.
淋巴瘤是免疫抑制常见的机会性并发症。获得性免疫缺陷综合征（AIDS）患者的淋巴瘤大致可分为四大类：中高级别全身性淋巴瘤、原发性中枢神经系统（CNS）淋巴瘤、霍奇金病（HD）和原发性渗出性淋巴瘤。已确定多种积极的治疗方案用于治疗与艾滋病相关的全身性淋巴瘤患者。然而，尽管初始完全缓解率较高，但大多数研究报告这些患者的中位生存期不到1年，约一半的患者死于淋巴瘤，另一半死于机会性感染或其他与艾滋病相关的并发症。艾滋病相关原发性中枢神经系统淋巴瘤患者的标准治疗方法是放疗，尽管最近使用化疗与放疗联合的研究可能会改善这组总体预后很差的患者的治疗效果。实体器官或骨髓移植后患者的淋巴增殖性疾病表现为一系列病症。对于这组患者，尚未明确确立标准的治疗方法。
